Chemotherapy-Induced Neutropenia (CIN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chemotherapy-Induced Neutropenia (CIN) Market Outlook

Thelansis’s “Chemotherapy-Induced Neutropenia (CIN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Neutropenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chemotherapy-Induced Neutropenia Overview

Neutropenia is a severe adverse effect frequently associated with cancer chemotherapy. Loss of neutrophils disrupts immune defense mechanisms and increases the likelihood of infections. Infections lead to fever, known as febrile neutropenia (FN). Neutrophils generally comprise approximately half to two-thirds of all white blood cells (immune cells) and protect against bacterial infections. Patients who develop neutropenia may have a higher-than-normal risk of infections, and the severity of subsequent infections is also higher. Chemotherapeutic agents act on the bone marrow, where active cell division occurs, and deplete hematopoietic stem cells, leading to a decreased circulating absolute neutrophil count. Patients receiving chemotherapy have been reported to experience a temporary reduction in their neutrophil counts. Chemotherapy-induced neutropenia (CIN) remains a common dose-limiting toxicity for chemotherapeutic agents, causing treatment delays and/or dose reductions. According to this grading system, neutropenia is classified according to the following four grades: (i) Grade 1 with an ANC of 1,500–2,000 cells/mm3, (ii) Grade 2 with an ANC of 1,000–1,500 cells/mm3, (iii) Grade 3 with an ANC of 500–1,000 cells/mm3, and (iv) Grade 4 with an ANC < 500 cells/mm3. Currently, the standard chemotherapy-induced neutropenia treatment uses a granulocyte colony-stimulating factor (G-CSF) to attenuate white blood cell counts and absolute neutrophil counts (ANCs). G-CSFs are frequently used to decrease the incidence and duration of chemotherapy-induced neutropenia.

• The incidence of Chemotherapy-induced neutropenia in the US is 2.4-15.4 cases/million each year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: